European Society for Medical Oncology Advanced Course on Deep Dive in CDK4-6 Inhibitors Data in Breast Cancer Dubai 2023
Format: 9 videos + 10 pdfs, size: 7.58 GB
Course Audience: oncologist
Overview:
- Start date 20 May 2023
- End date 20 May 2023
- Location Dubai, United Arab Emirates
Learning objectives
- Understanding the function and biology of CDK4-6 in malignant breast cancer cells
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the metastatic setting
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
- Providing an outlook of potential integration of CDK 4-6 inhibitors in the adjuvant setting
- Discussing clinical cancer cases to integrate use of CDK 4-6 inhibitors in clinical practice
Programme (PDF Format)
Session 1 Cont Clinical cases of high-risk patients with early HR positive HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors Balancing efficacy and toxicity (Video MP4 Format)Session 1 Cont Clinical cases of high-risk patients with early HR positive HER2 negative breast cancer candidate to adjuvant CDK4-6 inhibitors Balancing efficacy and toxicity (PDF Format)Session 1 Integrating CDK4-6 inhibitors in patients with early HR positive HER2 negative breast cancer Successes and failures (Video MP4 Format)Session 1 Integrating CDK4-6 inhibitors in patients with early HR positive HER2 negative breast cancer Successes and failures (PDF Format)Session 1 Ongoing clinical studies on CDK4-6 inhibition in early HR positive HER2 negative breast cancer (Video MP4 Format)Session 1 Ongoing clinical studies on CDK4-6 inhibition in early HR positive HER2 negative breast cancer (PDF Format)Session 1 Risk stratification in HR positive HER2 negative early breast cancer Lessons from neoadjuvant and adjuvant setting (Video MP4 Format)Session 1 Risk stratification in HR positive HER2 negative early breast cancer Lessons from neoadjuvant and adjuvant setting (PDF Format)Session 2 CDK4-6 inhibition in patients with metastatic HR positive HER2 negative breast cancer Benefit in endocrine resistant disease (Video MP4 Format)Session 2 CDK4-6 inhibition in patients with metastatic HR positive HER2 negative breast cancer Benefit in endocrine resistant disease (PDF Format)Session 2 Emerging data on new agents and new combinations in endocrine resistant disease (Video MP4 Format)Session 2 Emerging data on new agents and new combinations in endocrine resistant disease (PDF Format)Session 3 CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting (Video MP4 Format)Session 3 CDK4-6 inhibitors beyond CDK4-6 inhibitors in metastatic setting (PDF Format)Session 3 Role of CD 4-6 inhibitors across enriched molecular subgroup (Video MP4 Format)Session 3 Role of CD 4-6 inhibitors across enriched molecular subgroup (PDF Format)Welcome and introduction (Video MP4 Format)Welcome and introduction (PDF Format)